Jim Cook, DO
Family Medicine · Wasilla, AKNPI 1528353877
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 308 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by AbbVie at 24.8% of the total. Among family medicine clinicians in AK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 308 payments — averaging $18.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$577
- Pfizer$422
- Amgen$416
- Astellas Pharma US Inc$347
- Lilly USA, LLC$330
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,606100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 70 | $1,395 |
| AstraZeneca | 36 | $577 |
| Pfizer | 25 | $422 |
| Amgen(2 entities) | 24 | $416 |
| Astellas Pharma US Inc | 16 | $347 |
| Lilly USA, LLC | 21 | $330 |
| Novo Nordisk | 21 | $301 |
| GSK | 14 | $230 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $193 |
| Sanofi-aventis U.S. LLC | 5 | $153 |
| Novartis | 9 | $148 |
| Johnson & Johnson | 6 | $112 |
| Teva Pharmaceuticals USA, Inc. | 5 | $97 |
| Eisai Inc. | 6 | $89 |
| Daiichi Sankyo Inc. | 3 | $77 |
| Exact Sciences | 3 | $75 |
| Bayer | 3 | $75 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $70 |
| Amarin Pharma, Inc. | 4 | $70 |
| Biohaven Pharmaceuticals, Inc. | 3 | $65 |
| Boehringer Ingelheim | 3 | $62 |
| Abbott | 2 | $59 |
| Merck | 4 | $49 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $46 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Lundbeck LLC | 1 | $16 |
| Mylan Specialty L.p. | 1 | $16 |
| Pharmacosmos Therapeutics Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Inspire Medical Systems, Inc. | 1 | $15 |
| Aimmune Therapeutics, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
How this compares
$5,618 in reported general payments places this provider in the 95th percentile of 334 family medicine providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 36 | $57,674 |
| EliquisApixaban | 24 | $35,050 |
| FarxigaDapagliflozin Propanediol | 20 | $34,298 |
| JanuviaSitagliptin Phosphate | 22 | $24,538 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $23,036 |
| JardianceEmpagliflozin | 17 | $21,192 |
| MyrbetriqMirabegron | 13 | $13,327 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $7,859 |
| Diclofenac Sodium | 13 | $4,497 |
| Bupropion XlBupropion Hcl | 11 | $4,419 |
| Nebivolol Hcl | 24 | $3,026 |
| Celecoxib | 23 | $2,494 |
| Atorvastatin Calcium | 179 | $2,319 |
| Ventolin HfaAlbuterol Sulfate | 20 | $1,863 |
| Tamsulosin Hcl | 52 | $1,657 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $301 | $57,67436 claims |
| PfizerEliquis | $422 | $35,05024 claims |
| AstraZenecaFarxiga | $577 | $34,29820 claims |
| MerckJanuvia | $49 | $24,53822 claims |
| GSKTrelegy Ellipta | $230 | $23,03622 claims |
| Boehringer IngelheimJardiance | $62 | $21,19217 claims |
| Astellas Pharma US IncMyrbetriq | $347 | $13,32713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 334 family medicine providers in Alaska.
Other family medicine in Wasilla
- Ray KelleyWasilla$9K
- Frank GreathouseWasilla$7K
- Jessica JachimiecWasilla$6K
- Tracy SlagerWasilla$5K
- Joyce RestadWasilla$5K
- Wade EricksonWasilla$3K
- Valerie KrozelWasilla$3K
- Sarah HennemannWasilla$3K
- Nathan GeorgeWasilla$3K
- Jaron MinerWasilla$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.